Effect of CYP3A5*3 polymorphism on anti-inflamatory therapy in children with bronchial asthma
Previous pharmacogenetic studies demonstrate significant genes’ polymorphisms effect on the efficacy and safety of pharmacotherapy, including in bronchial asthma (BA). According to the literature, there are data on the effect of polymorphisms CYP3A4*22 and CYP3A5*3 on the efficacy of inhaled cortico...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2019-07-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/3095 |
| _version_ | 1797841429406416896 |
|---|---|
| author | A. K. Zastrozhina S. V. Zaitseva E. A. Grishina K. A. Ryzhykova O. O. Panfeorova S. Y. Kalenov O. I. Soboleva D. A. Sychyov I. N. Zakharova |
| author_facet | A. K. Zastrozhina S. V. Zaitseva E. A. Grishina K. A. Ryzhykova O. O. Panfeorova S. Y. Kalenov O. I. Soboleva D. A. Sychyov I. N. Zakharova |
| author_sort | A. K. Zastrozhina |
| collection | DOAJ |
| description | Previous pharmacogenetic studies demonstrate significant genes’ polymorphisms effect on the efficacy and safety of pharmacotherapy, including in bronchial asthma (BA). According to the literature, there are data on the effect of polymorphisms CYP3A4*22 and CYP3A5*3 on the efficacy of inhaled corticosteroids in children with BA. Further research on the effect of pharmacogenetic features on the efficacy and safety of drugs is one of the way to optimize asthma therapy in children.Purpose. Identification of possible ways to optimize asthma therapy by the analysis of CYP3A5 (A6986G) gene polymorphism effect on the asthma therapy efficacy.Materials and methods. The study was conducted on the basis of three children’s polyclinics of Moscow. 100 children aged 6–17 years with an established diagnosis of BA were included. Dynamic assessment of asthma control and the amount of therapy needed was carried out. All patients underwent genotyping for the A6986G polymorphism of CYP3A5 gene by real-time PCR. Statistical data analysis was carried out using a programming language for statistical data processing R.3.4.0.Results. It was found that 8% of children with asthma were heterozygous for the A6986G polymorphism of the CYP3A5 gene, 92% of respondents were homozygous with the GG genotype. In 6 out of 8 heterozygotes, the amount of control therapy corresponded the third and fourth therapy stages according to GINA criteria. In the group of moderate and severe BA, the number of heterozygotes for the A6986G polymorphic marker of the CYP3A5 gene was statistically higher compared to the group of children with mild BA (p = 0,048).Conclusion. Thus, we identified a statistically significant difference in the occurrence of heterozygotes for the A6986G polymorphism of the CYP3A5 gene between groups of children with mild asthma and patients with moderate and severe asthma. The AG genotype and the presence of the A allele (CYP3A5 gene (A6986G)) are associated with more severe BA and the need for more anti-inflammatory therapy. |
| first_indexed | 2024-04-09T16:30:40Z |
| format | Article |
| id | doaj.art-5f0e933c47314ad28c74d7ef3dd7d9e1 |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:30:40Z |
| publishDate | 2019-07-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-5f0e933c47314ad28c74d7ef3dd7d9e12023-04-23T06:57:06ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902019-07-0101114615110.21518/2079-701X-2019-11-146-1513005Effect of CYP3A5*3 polymorphism on anti-inflamatory therapy in children with bronchial asthmaA. K. Zastrozhina0S. V. Zaitseva1E. A. Grishina2K. A. Ryzhykova3O. O. Panfeorova4S. Y. Kalenov5O. I. Soboleva6D. A. Sychyov7I. N. Zakharova8State Budgetary Institution of Healthcare of the city of Moscow Children’s City Polyclinic No. 42 of the Department of Healthcare of the city of MoscowFederal State Budgetary Educational Institution of the Higher Education Moscow State University of Medicine and Dentistry named after A.I. Yevdokimov of the Ministry of Healthcare of the Russian FederationFederal State Budgetary Educational Institution of Additional Professional Education Russian Medical Academy of Continuing Professional Education of the Ministry of Health of the Russian FederationFederal State Budgetary Educational Institution of Additional Professional Education Russian Medical Academy of Continuing Professional Education of the Ministry of Health of the Russian FederationState Budgetary Institution of Healthcare of the city of Moscow Children’s City Polyclinic No. 42 of the Department of Healthcare of the city of MoscowState Budgetary Institution of Healthcare of the city of Moscow Children’s City Polyclinic No. 42 of the Department of Healthcare of the city of MoscowState Budgetary Institution of Healthcare of the city of Moscow Children’s City Polyclinic No. 42 of the Department of Healthcare of the city of MoscowFederal State Budgetary Educational Institution of Additional Professional Education Russian Medical Academy of Continuing Professional Education of the Ministry of Health of the Russian FederationFederal State Budgetary Educational Institution of Additional Professional Education Russian Medical Academy of Continuing Professional Education of the Ministry of Health of the Russian FederationPrevious pharmacogenetic studies demonstrate significant genes’ polymorphisms effect on the efficacy and safety of pharmacotherapy, including in bronchial asthma (BA). According to the literature, there are data on the effect of polymorphisms CYP3A4*22 and CYP3A5*3 on the efficacy of inhaled corticosteroids in children with BA. Further research on the effect of pharmacogenetic features on the efficacy and safety of drugs is one of the way to optimize asthma therapy in children.Purpose. Identification of possible ways to optimize asthma therapy by the analysis of CYP3A5 (A6986G) gene polymorphism effect on the asthma therapy efficacy.Materials and methods. The study was conducted on the basis of three children’s polyclinics of Moscow. 100 children aged 6–17 years with an established diagnosis of BA were included. Dynamic assessment of asthma control and the amount of therapy needed was carried out. All patients underwent genotyping for the A6986G polymorphism of CYP3A5 gene by real-time PCR. Statistical data analysis was carried out using a programming language for statistical data processing R.3.4.0.Results. It was found that 8% of children with asthma were heterozygous for the A6986G polymorphism of the CYP3A5 gene, 92% of respondents were homozygous with the GG genotype. In 6 out of 8 heterozygotes, the amount of control therapy corresponded the third and fourth therapy stages according to GINA criteria. In the group of moderate and severe BA, the number of heterozygotes for the A6986G polymorphic marker of the CYP3A5 gene was statistically higher compared to the group of children with mild BA (p = 0,048).Conclusion. Thus, we identified a statistically significant difference in the occurrence of heterozygotes for the A6986G polymorphism of the CYP3A5 gene between groups of children with mild asthma and patients with moderate and severe asthma. The AG genotype and the presence of the A allele (CYP3A5 gene (A6986G)) are associated with more severe BA and the need for more anti-inflammatory therapy.https://www.med-sovet.pro/jour/article/view/3095bronchial asthmaanti-inflammatory therapyinhaled glucocorticoidspharmacogeneticscyp3a5 |
| spellingShingle | A. K. Zastrozhina S. V. Zaitseva E. A. Grishina K. A. Ryzhykova O. O. Panfeorova S. Y. Kalenov O. I. Soboleva D. A. Sychyov I. N. Zakharova Effect of CYP3A5*3 polymorphism on anti-inflamatory therapy in children with bronchial asthma Медицинский совет bronchial asthma anti-inflammatory therapy inhaled glucocorticoids pharmacogenetics cyp3a5 |
| title | Effect of CYP3A5*3 polymorphism on anti-inflamatory therapy in children with bronchial asthma |
| title_full | Effect of CYP3A5*3 polymorphism on anti-inflamatory therapy in children with bronchial asthma |
| title_fullStr | Effect of CYP3A5*3 polymorphism on anti-inflamatory therapy in children with bronchial asthma |
| title_full_unstemmed | Effect of CYP3A5*3 polymorphism on anti-inflamatory therapy in children with bronchial asthma |
| title_short | Effect of CYP3A5*3 polymorphism on anti-inflamatory therapy in children with bronchial asthma |
| title_sort | effect of cyp3a5 3 polymorphism on anti inflamatory therapy in children with bronchial asthma |
| topic | bronchial asthma anti-inflammatory therapy inhaled glucocorticoids pharmacogenetics cyp3a5 |
| url | https://www.med-sovet.pro/jour/article/view/3095 |
| work_keys_str_mv | AT akzastrozhina effectofcyp3a53polymorphismonantiinflamatorytherapyinchildrenwithbronchialasthma AT svzaitseva effectofcyp3a53polymorphismonantiinflamatorytherapyinchildrenwithbronchialasthma AT eagrishina effectofcyp3a53polymorphismonantiinflamatorytherapyinchildrenwithbronchialasthma AT karyzhykova effectofcyp3a53polymorphismonantiinflamatorytherapyinchildrenwithbronchialasthma AT oopanfeorova effectofcyp3a53polymorphismonantiinflamatorytherapyinchildrenwithbronchialasthma AT sykalenov effectofcyp3a53polymorphismonantiinflamatorytherapyinchildrenwithbronchialasthma AT oisoboleva effectofcyp3a53polymorphismonantiinflamatorytherapyinchildrenwithbronchialasthma AT dasychyov effectofcyp3a53polymorphismonantiinflamatorytherapyinchildrenwithbronchialasthma AT inzakharova effectofcyp3a53polymorphismonantiinflamatorytherapyinchildrenwithbronchialasthma |